10 Small Firms Kick Off Monday with Strong Gains

7. Lexeo Therapeutics Inc. (NASDAQ:LXEO)

Lexeo grew its share prices for a second straight day on Monday, rallying by as much as 57.56 percent at intra-day trading before finishing the day just up by 50.92 percent at $4.09 apiece.

Investor sentiment was largely fueled by the company’s optimistic outlook about the LX2020, its treatment candidate for arrhythmogenic cardiomyopathy.

In a statement, LXEO CEO Richard Nolan Townsend said the company was encouraged by the favorable safety profile and early data observed in participants dosed with LX2020 to date.

According to the company, LX2020 has so far been generally well tolerated with no treatment-related serious adverse events to date across both dose cohorts.

“We look forward to sharing additional clinical updates later in 2025 now that the second cohort of the LX2020 HEROIC-PKP2 Phase 1/2 trial in arrhythmogenic cardiomyopathy is fully enrolled,” he added.

On the same day, LXEO reported its latest quarterly earnings performance, with net loss widening by 82.7 percent to $25.924 million in the fourth quarter of 2024 from $14.188 million in the same period a year earlier.

Meanwhile, net loss for the full-year period also widened by 48 percent to $98.3 million from $66.4 million in 2023.